Copper oxide–ferric oxide nanocomposite: Synthesis, characterization, and antibacterial and antifungal properties

Mohamed Elnouby; Marwa Nabil; Abdulaziz A. Al-Askar; Przemysław Kowalczewski; Said Behiry; Ahmed Abdelkhalek

doi:10.2478/msp-2024-0035

.blurhash-client-img { display: none !important; }

Copper oxide–ferric oxide nanocomposite: Synthesis, characterization, and antibacterial and antifungal properties

Materials Science-Poland

Volume 42 (2024): Issue 3 (September 2024)

By: Mohamed Elnouby, Marwa Nabil, Abdulaziz A. Al-Askar, Przemysław Kowalczewski, Said Behiry and Ahmed Abdelkhalek

Open Access

|Nov 2024

Figures & Tables

XRD pattern of the prepared nanoparticles; CuO, Fe₂O₃, and the NC CuO/Fe₂O₃.

Table 1

Calculated crystal sizes of the obtained quantum dot.

Peak	2Ɵ	Plane	FWHM	Size (nm)
1	35.61	−111 (CuO)	1.235	7
2	43.37	400 (CuO/Fe₂O₃)	0.7399	12
3	44.73	−112 (CuO)	0.842	10.6
4	31.25	110 (CuO)	0.963	9

FTIR spectrum of the prepared NC (CuO/Fe₂O₃).

EDX analysis of the obtained NC (CuO/Fe₂O₃).

TEM micrograph of the obtained NC (CuO/Fe₂O₃).

Table 2

Hyphal growth response of the fungal isolates to series concentrations of CuO/Fe₂O₃-NCcompared to copper formate after 7 days of incubation.

Concentrations (µg/mL)	Growth response (diameter [mm] ± SD1; inhibition [%])
	Fusarium oxysporum		Botrytis cinerea		Rhizoctonia solani
	(OR116510)		(OR116494)		(OR116531)
25	29.3 ± 0.58^b	67.4	53.7 ± 4.04^b	40.4	19.7 ± 0.58^b	78.2
50	28.0 ± 1.73^b,c	68.9	50.0 ± 0.00^b,c	44.4	18.0 ± 0.00^c	80.0
75	26.3 ± 1.53^c,d	70.7	46.3 ± 1.15^c,d	48.5	18.0 ± 0.00^c	80.0
100	26.0 ± 0.00^d	71.1	45.0 ± 3.00^d	50.0	17.0 ± 0.00^d	81.1
−ve control2	90.0 ± 0.00^a	0.00	90.0 ± 0.00^a	0.00	90.0 ± 0.00^a	0.00
+ ve control3	25.7 ± 1.15^d	71.5	46.7 ± 0.58 cd	48.5	16.0 ± 1.00^e	82.2

Similarity in the letters adjacent to the growth values in each column is not significantly distinguished as per the LSD_0.05.

1 Standard deviation.

2 Without CuO/Fe₂O₃-NC treatment.

3 Copper formate (100 µg/mL).

Table 3

Inhibition zone of the bacterial isolates to series concentrations of CuO/Fe₂O₃-NC compared to gentamicin.

Concentrations (µg/mL)	Inhibition zone (diameter [mm] ± SD1)
Concentrations (µg/mL)	P. carotovorum	S. scabies	P. atrosepticum	R. solanacearum
10	11.0 ± 0.00^b	9.00 ± 0.00^b	9.00 ± 0.00^c	10.7 ± 0.58^d
20	11.0 ± 0.00^b	9.00 ± 0.00^b	9.00 ± 0.00^c	11.0 ± 0.00^d
30	11.7 ± 0.58^b	9.00 ± 0.00^b	9.00 ± 0.00^c	11.0 ± 0.00^d
40	11.7 ± 0.58^b	9.00 ± 0.00^b	9.33 ± 0.58^c	12.0 ± 0.00^c
50	12.3 ± 1.15^b	9.00 ± 0.00^b	10.7 ± 0.58^b	14.7 ± 0.58^b
−ve control2	0.00 ± 0.00^c	0.00 ± 0.00^c	0.00 ± 0.00^d	0.00 ± 0.00^e
+ ve control3	19.0 ± 1.73^a	41.7 ± 2.89^a	16.00 ± 1.73^a	25.0 ± 0.00^a

Similarity in the letters adjacent to the growth values in each column is not significantly distinguished as per the LSD_0.05.

1 Standard deviation.

2 Without CuO/Fe₂O₃-NC treatment.

3 Gentamicin (30 µg/disc).

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/msp-2024-0035 | Journal eISSN: 2083-134X (formerly 2083-124X) | Journal ISSN: 2083-1331

Journal RSS Feed

Language: English

Page range: 100 - 110

Submitted on: Jun 12, 2024

Accepted on: Sep 19, 2024

Published on: Nov 8, 2024

Published by: Wroclaw University of Science and Technology

In partnership with: Paradigm Publishing Services

Keywords:

Copper oxide–ferric oxide,

Nanocomposite,

TEM,

FTIR,

Antibacterial,

Antifungal

Related subjects:

Materials sciences,

Materials sciences, other,

Nanomaterials,

Functional and smart materials,

Materials characterization and properties

© 2024 Mohamed Elnouby, Marwa Nabil, Abdulaziz A. Al-Askar, Przemysław Kowalczewski, Said Behiry, Ahmed Abdelkhalek, published by Wroclaw University of Science and Technology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 42 (2024): Issue 3 (September 2024)

Copper oxide–ferric oxide nanocomposite: Synthesis, characterization, and antibacterial and antifungal properties

Figures & Tables

Figure 1

Table 1

Figure 2

Figure 3

Figure 4

Table 2

Table 3

Paradigm

My account